Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Trilaciclib with Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer
2016-004466-26Phase 2Completed
- Sponsor
- G1 Therapeutics, Inc.
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trilaciclib in triple-negative breast cancer (TNBC) and breast cancer, sponsored by G1 Therapeutics, Inc. Primary endpoint: Safety and tolerability of trilaciclib with gemcitabine and carboplatin. Started Jun 2017; status: completed.
02
Drugs
trilaciclib
03
Conditions
triple-negative breast cancer (TNBC)breast cancer
Beyond the preview
Go deeper on 2016-004466-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004466-26.